Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rigel Pharmaceuticals
The study is a multi-center, randomized, double-blind, placebo-controlled, parallel group study comparing 2 doses of inhaled R343 bid to placebo over 8 weeks in patients with mild to moderate allergic asthma. Patients who meet specific inclusion and exclusion criteria after an initial screening evaluation and a single-blind, run-in period will be randomized to receive either R343 or placebo.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical history of asthma
Ability to perform spirometry
You may not be if
Chronic obstructive pulmonary disease or bronchiectasis